-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SFRCWUr9l4cCS3E5dSaWRPBcz8K5+jWlF+zfeVtCLTTalCBfJLIuH68hhrKXW5Ao
 LafJuKFoJnYl3wSxkkh+Fw==

<SEC-DOCUMENT>0000927946-04-000155.txt : 20040804
<SEC-HEADER>0000927946-04-000155.hdr.sgml : 20040804
<ACCEPTANCE-DATETIME>20040804135509
ACCESSION NUMBER:		0000927946-04-000155
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040726
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20040804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		04950992

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8k.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC. - 8K
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>July 26, 2004</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u>Indiana</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
0-23357</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
35-1345024</u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
2701 Kent Avenue<br>
<u>West Lafayette, Indiana</u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u>47906-1382</u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
(765) 463-4527</u></font></TD></TR>
<TR VALIGN=top>
<TD>&nbsp;</TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>

<PAGE>


<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
The information in this Form 8-K is being furnished and shall not be deemed
"filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section. The
information in this Form 8-K shall not be incorporated by reference into any
registration statement or other document pursuant to the Securities Act of 1933,
as amended.</font></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements
and Exhibits.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.<BR>
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.<BR>
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits<BR>
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bioanalytical Systems, Inc. press release, issued July 26, 2004.
</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD
Disclosure.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
On July 26, 2004, Bioanalytical Systems, Inc. (the "Company") issued a press
release announcing that the Company has reached an agreement (in principle)
providing for the sale and leaseback of the building that currently houses its
clinical research facility in downtown Baltimore, Maryland. BASi will receive
$7.75 million in cash from the transaction and will lease 85% of the building
for two years at near market rate. Proceeds from the transaction will be used to
reduce debt. Closing of the transaction is subject to satisfactory completion of
due diligence and execution of a definitive purchase agreement.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
The full text of the press release is furnished as exhibit 99.1 to this Form
8-K.</font></P>


<PAGE>



<!-- MARKER FORMAT-SHEET="ARTICLE bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SIGNATURES</FONT></H1>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>


<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;August 4, 2004</FONT></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc.<BR>
<BR>
<BR>
<BR>

By:&nbsp;&nbsp;/s/ Michael R. Cox<hr>
Michael R. Cox<BR>
VP-Finance, Chief Financial Officer and<BR>
Treasurer
</FONT></Td>
</TR>
</TABLE>
<BR>


<PAGE>


<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B><U>Exhibit Index</U></B></font></P>
<BR>


<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10%><div align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit No.</U><BR>
<BR>
99.1</FONT></div></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description</U><BR>
<BR>
Bioanalytical Systems, Inc. press release, issued July 26, 2004.
</FONT></TD>
</TR>
</TABLE>
<BR>






</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 26, 2004
<TEXT>

<HTML>
<HEAD>
<TITLE>Exhibit 99.1 - Bioanalytical Systems, Inc.</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Heading Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit 99.1</U></FONT></H1>


<P ALIGN=right><FONT FACE="Times New Roman, Times, Serif" size=1>
<B>FOR MORE INFORMATION:</B><BR>
Bioanalytical Systems, Inc.<BR>
Michael R. Cox, 765-497-5829<BR>
<U>mcox@bioanalytical.com</U><BR>
- --OR--<BR>
Evan Smith, CFA/Erica Pettit<BR>
KCSA Worldwide<BR>
212.896.1251/212.896.1248<BR>
<U>esmith@kcsa.com</U>/epettit@kcsa.com<BR>
</font></P>
<BR>


<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Bioanalytical Systems, Inc. Announces $7.75 Million Sale-Leaseback of
Baltimore Facility</b>
</FONT></P>
<BR>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
WEST LAFAYETTE, Ind &#151; July 26, 2004 &#151; Bioanalytical Systems, Inc.
(Nasdaq:<U>BASI</U> &#151; <U>News</U>) today announced that it has reached an
agreement (in principle) providing for the sale and leaseback of the building
that currently houses its clinical research facility in downtown Baltimore,
Maryland. BASi will receive $7.75 million in cash from the transaction and will
lease 85% of the building for two years at near market rate. Proceeds from the
transaction will be used to reduce debt. Closing of the transaction is subject
to satisfactory completion of due diligence and execution of a definitive
purchase agreement.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc. is a pharmaceutical development company providing
contract research services and monitoring instruments to the world&#146;s
leading drug development and medical device companies. BASi focuses on
developing innovative services and products that increase efficiency and reduce
costs associated with taking new drugs to market. Visit
<U>www.bioanalytical.com</U> for more about BASi.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to
the development of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks
detailed in the company&#146;s filings with the Securities and Exchange
Commission.</FONT></P>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
